glp-1 coverage news The agency's “GLP-1 Bridge Program” will begin next month, allowing certain Medicare Part D enrollees to receive for select medications US health agency unveils weight-loss

Physicians on Sermo share experiences with GLP-1 weight loss drugs and risks

This article reviews the efficacy and safety of different strategies to initiate and intensify basal insulin, with focus on new fixed ratio combinations of basal insulin with GLP-1 RAs available for use in a single injection pen (insulin degludec/liraglutide and insulin glargine/lixisenatide).

The answer is yes

Time-of-onset analysis revealed no consistent mechanism for the latency of SSIBs in patients receiving GLP-1RAs

GLP-1 drugs like Ozempic have transformed weight management, but concerns around muscle loss, bone density, dampened desire, and dependency are growing